Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia
Overall, inotuzumab as BT effectively reduces tumor burden but attenuates CAR-T expansion without compromising survival outcomes. As high tumor burden is a dominant driver of relapse and toxicity, the net effect of inotuzumab may be favorable in selected patients.
Authors
- Laura Pérez-Ortega (ORCID: https://orcid.org/0000-0001-8049-1716)
- Belén Sierro-Martínez
- Luzalba Sanoja-Flores (ORCID: https://orcid.org/0000-0002-9275-7793)
- Javier Delgado‐Serrano
- José González Campos (ORCID: https://orcid.org/0000-0003-4610-6874)
- Marta Reinoso‐Segura (ORCID: https://orcid.org/0000-0002-1859-9803)
- Estefanía García‐Guerrero (ORCID: https://orcid.org/0000-0002-3041-9860)
- Concepción Pérez de Soto
- Patricia Alcalde‐Mellado
- Águeda Molinos-Quintana (ORCID: https://orcid.org/0000-0003-4972-917X)
- Victoria Ruiz-Maldonado
- Josè Antonio Pérez-Simón (ORCID: https://orcid.org/0000-0003-3616-6101)
- Teresa Caballero‐Velázquez (ORCID: https://orcid.org/0000-0001-7487-3793)
- José María Pérez‐Hurtado
Institutions
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1725878
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00